Therapeutic vaccines could prove to be a good way to tackle cancer. A few shots and--it is hoped--only a few side effects, rather than long treatments with traditional chemotherapy drugs that make...
In the course of one short year, Dendreon CEO Mitch Gold went from biotech hero to zero as the long-anticipated rollout of the groundbreaking cancer vaccine Provenge stumbled badly out of the gate.
Merck KGaA and Oncothyreon ($ONTY) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set
It takes years in biotechnology to forge an enduring success. But failure is always just one false step away. Look at Dendreon ($DNDN). A little more than a year ago, the biotech pioneer was
Mitch Gold and his struggling biotech Dendreon ($DNDN) can't catch a break since disappointing Wall Street with lackluster sales of the prostate cancer drug Provenge. TheStreet announced Gold was
Celldex Therapeutics ($CLDX) reports that a small, single-arm study of its experimental brain cancer vaccine scored a significantly higher overall survival rate than the historical numbers on file.
Dr. Ralph Steinman became the subject of his own pioneering research in the field of immunology after he was diagnosed with pancreatic cancer four and half years ago. After winning a Nobel prize this
In an attempt to break even in the cash-intensive biotech game following a rough start with its prostate cancer drug, Dendreon is handing pink slips to a quarter of its employees and saying goodbye
Struggling to break out of Wall Street's dog house, Dendreon is pursuing a corporate restructuring plan that many expect to result in big cost cuts and the potential elimination of jobs at the
After months of poor sales, Dendreon ($DNDN) terminated its Provenge contract with GlaxoSmithKline ($GSK). The pharma giant would have provided the cancer vaccine's antigen through 2015 as part of